A method for proliferating and / or differentiating t cells
Patent Information
- Application Number
- HK42026126214
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-09-20
- Filing Date
- 2026-07-16
- Publication Date
- 2026-09-11
Smart Images

Figure 00000022_0000 
Figure 00000022_0001 
Figure 00000022_0002
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202511349050.5 (22) Application Date 2025.09.18 (66) Domestic Priority Data 202411311344.4 2024.09.20 CN (71) Applicant Nova (Hong Kong) Holdings Limited Address Room A1, 11 / F, Success Commercial Building, 245-251 Hennessy Road, Wan Chai District, Hong Kong, China (72) Inventors Li Yongqin He Xiaowen (74) Patent Agency Shanghai Dianshi Intellectual Property Agency (General Partnership) 31309 Patent Attorney Zhang Zheng Jiang Fangwei (51) Int.Cl. C12N 5 / 0783 (2010.01) C12N 5 / 074 (2010.01) C12N 5 / 0789 (2010.01) (54) Title of Invention: A Method for Proliferating and / or Differentiating T Cells (57) Abstract: This application relates to a method for proliferating and / or differentiating T cells, comprising the steps of culturing pluripotent cells using Rho activator I / II and proliferating and / or differentiating the pluripotent cells into T cells. This application also provides a culture medium, culture platform, and application for culturing pluripotent cells and proliferating and / or differentiating them into T cells. Claims: 1 page Description: 20 pages Drawings: 11 pages CN 121699861 A 2026.03.20 CN 1 21 69 98 61 A 1. A method for proliferating and / or differentiating T cells, comprising culturing pluripotent cells using Rho activator I / II and proliferating and / or differentiating the pluripotent cells into T cells. 2. The method according to claim 1, wherein the Rho activator I / II is selected from one or more activators of the group consisting of CN02, CN03, and CN04. 3. The method according to any one of claims 1-2, wherein the method comprises culturing pluripotent cells using Rho activator I / II for 24-48 hours. 4. The method according to any one of claims 1-3, wherein the concentration of Rho activator I / II is 150-350 ng / mL. 5. The method according to any one of claims 1-4, wherein the method comprises culturing cells under hypoxic conditions.6. The method according to any one of claims 1-5, wherein the method comprises culturing pluripotent cells using a culture medium comprising one or more of the following factors: CHIR99021, Y-27632, GlutaMAX, L-ascorbic acid, MTG, ITS, BMP4, VEGF, bFGF, SB431542, SCF, TPO, FLT3, Sodium Pyruvate, β-Mercaptoethanol, NEAA, IL-7, IL-15, SB203580, SDF-1α, Dexamethasone, IL-21, and Anti-CD3 OKT3. 7. A culture medium for culturing pluripotent cells and differentiating them into T cells, wherein the culture medium comprises Rho activator I / II. 8. The culture medium according to claim 7, wherein the Rho activator I / II is selected from one or more activators of the group consisting of CNO2, CNO3, and CNO4. 9. The culture medium according to any one of claims 7-8, wherein the concentration of Rho activator I / II is 150-350 ng / mL. 10. The culture medium according to any one of claims 7-9, comprising one or more of the following factors: CHIR99021, Y-27632, GlutaMAX, L-ascorbic acid, MTG, ITS, BMP4, VEGF, bFGF, SB 431542, SCF, TPO, FLT3, Sodium Pyruvate, β-Mercaptoethanol, NEAA, IL-7, IL-15, SB203580, SDF-1α, Dexamethasone, IL-21, and Anti-CD3 OKT3. Claims 1 / 1 page 2 CN 121699861 A Method for Proliferating and / or Differentiating T Cells Technical Field
[0001] This application relates to the field of biomedicine, specifically to a method for proliferating and / or differentiating T cells, and the culture medium used in this method and its application. Background Art
[0002] Human induced pluripotent stem cells (iPSCs) have unlimited proliferative capacity and can differentiate into all types of cells in the body, including hematopoietic stem cells used for cell therapy, as well as T, B, NKT, and NK lymphocytes, making them an ideal source of allogeneic immune cells. iPSCs can also be genetically modified to enhance their specificity and effector functions, producing a large number of tumor antigen-specific T and NK cells in vitro and enhancing their persistence after reinfusion into the body.Currently, the process of inducing immune cell production from iPSCs in vitro typically involves the stepwise addition of small molecules or cell growth factors to activate important signaling pathways, mimicking a series of blood and immune system development processes during embryonic and fetal development. A crucial intermediate step is the ability to induce hematopoietic stem cells with lymphocyte differentiation potential. This is because at least two temporary and spatially unique waves of blood formation occur during embryonic development: primitive hematopoiesis and permanent hematopoiesis. Only during permanent hematopoietic development, newly generated hematopoietic stem cells from arterial endothelial cells undergo a series of developmental and maturation processes to maintain adult multi-lineage hematopoiesis and generate T, B, NK, and NKT lymphocytes. Although several reported differentiation protocols can generate hematopoietic stem cells from human iPSCs, most protocols promote primitive hematopoiesis. The resulting hematopoietic stem cells cannot undergo long-term self-renewal, multi-lineage differentiation, or have engraftment potential, and cannot be effectively differentiated into T cells and NK cells, among other lymphocytes.
[0003] Therefore, the reported methods for inducing iPSCs to generate T and NK cells and other lymphocytes have difficulties such as low yield, complex production process (sorting is required during induction, which increases the difficulty of the experiment), and low safety (interference from foreign substances, feeder cells), which seriously hinder the industrialization and large-scale production application.
[0004] Existing methods for differentiating iPSCs into T cells and NK cells in vitro mostly use the embryonic body (EB) 3D suspension culture method in the hematopoietic stem cell stage. This requires centrifugation to allow the cells to settle and aggregate in microplates or to allow iPSCs to passively aggregate in the suspension culture to spontaneously form spheroids. However, the former method is complicated, time-consuming and labor-intensive, and not suitable for large-scale application. The latter method results in spheroids of uneven size, increased cell heterogeneity, and unstable yield and purity. In addition, most methods require the HPCs obtained by dissociating the spheroids into single cells at the differentiation endpoint for sorting to obtain CD34+ HPCs before they can enter the subsequent differentiation steps. Usually, the yield is very low and the operation is complicated.
[0005] To date, the molecular mechanism by which hematopoietic progenitor / stem cells develop into T cells in vivo has not been fully elucidated. Traditional methods for in vitro T cell differentiation use feeder cells or animal-derived components to maintain and induce cell differentiation, and the composition of the culture medium is unclear, which is far from meeting the safety requirements of biopharmaceuticals. Currently, a few differentiation methods can differentiate T cells in serum-free and feeder-free systems, but these methods cannot efficiently obtain late-stage and mature T cells.
[0006] Studies have shown that the generation of hematopoietic stem cells and lymphocytes such as T and NK cells from pluripotent stem cells depends on how well-designed and validated methods are used to induce early embryonic hematopoietic development towards permanent hematopoiesis. To meet the industrial demand for efficiently obtaining late-stage and mature T cells, there is an urgent need to develop a method for inducing iPSCs to differentiate into T cells.
[0007] This application provides a method for proliferating and / or differentiating T cells, which includes culturing pluripotent cells using Rho activator I / II (instruction manual page 1 / 20, 3 CN 121699861 A) and proliferating and / or differentiating the pluripotent cells into T cells.
[0008] The method provided by this application has one or more of the following advantages:
[0009] (1) The hematopoietic stem cell differentiation protocol used involves culturing cells on a shaker throughout the entire process. On the second day after iPSC single-cell seeding, uniformly sized EB spheres can spontaneously form. From the sixth day of differentiation, HPCs are gradually released into the suspension system. At the end of differentiation, only the suspension cells can be collected without digesting the EB spheres to obtain high-purity CD34+ HPCs. The amplification factor is 5 to 10 times, and it can be directly used for subsequent T and NK differentiation experiments without sorting. (2) When the differentiation system is expanded, the differentiation efficiency is high and reproducible. It can be conveniently applied to commercially available conical flasks or other large-scale cell production devices. Cell sampling and harvesting are easy at any time during the process. (3) By adding the small molecule compound CN03, the production of hematopoietic stem cells with lymphoid differentiation potential can be effectively promoted. At the same time, it can also significantly promote the generation of terminal T and NK cells and increase their yield. In particular, each iPSC can generate a large number of late mature T cells through differentiation. It has the typical T cell characteristics of CD5+ CD8αβ+ and has a high amplification capacity in vitro.
[0010] On the one hand, this application provides a method for proliferating and / or differentiating T cells, which includes culturing pluripotent cells using Rho activator I / II and proliferating and / or differentiating pluripotent cells into T cells. The pluripotent cells can be induced pluripotent stem cells (iPSCs), hematopoietic stem / progenitor cells (HPCs), and modified cells.
[0011] In some embodiments, the Rho activator I / II may be selected from one or more activators of the group consisting of CN02, CN03, and CN04. In some embodiments, the Rho activator II is CN02. In some embodiments, the Rho activator II is CN03. In some embodiments, the Rho activator I is CN04.
[0012] In some embodiments, the method includes culturing pluripotent cells using Rho activator I / II for 12-96 hours. In some embodiments, the method includes culturing pluripotent cells using Rho activator I / II for 12-72 hours. In some embodiments, the method includes culturing pluripotent cells using Rho activator I / II for 12-48 hours. In some embodiments, the method includes culturing pluripotent cells using Rho activator I / II for 24-48 hours.In some embodiments, the method includes culturing pluripotent cells using CNO3 for approximately 48 hours.
[0013] In some embodiments, the concentration of Rho activator I / II is 50-750 ng / mL. In some embodiments, the concentration of Rho activator I / II is 150-350 ng / mL. In some embodiments, the concentration of Rho activator I / II is approximately 250 ng / mL.
[0014] In some embodiments, the concentration of CNO3 is 50-750 ng / mL. In some embodiments, the concentration of CNO3 is 150-350 ng / mL. In some embodiments, the concentration of CNO3 is approximately 250 ng / mL.
[0015] In some embodiments, the T cells are CD5+CD7+ T precursor cells. In some embodiments, the T cells are CD5+CD8αβ+ T cells.
[0016] In some embodiments, the method includes culturing cells under hypoxic conditions. In some embodiments, the hypoxic condition is 5% O2. In some embodiments, the method includes culturing cells under serum-free culture conditions. In some embodiments, the method does not use feeder cells.
[0017] In some embodiments, the method includes culturing pluripotent cells using a culture medium containing one or more of the following factors: CHIR99021, Y-27632, GlutaMAX, L-ascorbic acid, MTG, ITS, BMP4, VEGF, bFGF, SB 431542, SCF, TPO, FLT3, Sodium Pyruvate, β-Mercaptoethanol, NEAA, IL-7, IL-15, SB203580, SDF-1α, Dexamethasone, IL-21, and Anti-CD3 OKT3.
[0018] In some embodiments, the method includes culturing pluripotent cells using a culture medium containing a basal medium. In some embodiments, the basal culture medium is selected from one or more of the following culture media: Nuwacell® ncTarget complete medium, Stempro-34 complete medium, and StemSpan SFEM II medium.
[0019] On the other hand, this application provides a culture medium for culturing pluripotent cells and differentiating pluripotent cells into T cells, the culture medium containing Rho activator I / II.
[0020] In some embodiments, the pluripotent cells in the culture medium are induced pluripotent stem cells (iPSCs).In some embodiments, the pluripotent cells in the culture medium are hematopoietic stem / progenitor cells (HPCs). In some embodiments, the pluripotent cells in the culture medium are modified cells.
[0021] In some embodiments, the Rho activator I / II in the culture medium is selected from one or more activators of the group consisting of CNO2, CNO3, and CNO4. In some embodiments, the Rho activator II in the culture medium is CNO2. In some embodiments, the Rho activator II in the culture medium is CNO3. In some embodiments, the Rho activator I in the culture medium is CNO4.
[0022] In some embodiments, the concentration of the Rho activator I / II in the culture medium is 50-750 ng / mL. In some embodiments, the concentration of the Rho activator I / II in the culture medium is 150-350 ng / mL. In some embodiments, the concentration of the Rho activator I / II in the culture medium is approximately 250 ng / mL. In some embodiments, the concentration of CNO3 in the culture medium is 50-750 ng / mL. In some embodiments, the concentration of CNO3 in the culture medium is 150-350 ng / mL. In some embodiments, the concentration of CNO3 in the culture medium is approximately 250 ng / mL.
[0023] In some embodiments, the T cells in the culture medium are CD5+CD7+ T precursor cells. In some embodiments, the T cells in the culture medium are CD5+CD8αβ+ T cells.
[0024] In some embodiments, the culture medium contains one or more of the following factors: CHIR99021, Y-27632, GlutaMAX, L-ascorbic acid, MTG, ITS, BMP4, VEGF, bFGF, SB 431542, SCF, TPO, FLT3, Sodium Pyruvate, β-Mercaptoethanol, NEAA, IL-7, IL-15, SB203580, SDF-1α, Dexamethasone, IL-21, and Anti-CD3 OKT3.
[0025] In some embodiments, the culture medium contains a basal culture medium selected from one or more of the following culture media: Nuwacell® ncTarget complete medium, Stempro-34 complete medium, and StemSpan SFEM II medium.
[0026] On the other hand, this application provides a composition comprising pluripotent cells and the culture medium described in this application.
[0027] On the other hand, this application provides a culture platform for obtaining T cells, which includes the method described in this application and / or the culture medium described in this application.
[0028] Other aspects and advantages of this application will be readily apparent to those skilled in the art from the following detailed description. The following detailed description shows and describes only exemplary embodiments of this application. As those skilled in the art will recognize, the content of this application enables them to make modifications to the specific embodiments disclosed without departing from the spirit and scope of the invention involved in this application. Accordingly, the descriptions in the drawings and specification of this application are merely exemplary and not restrictive. Brief Description of the Drawings
[0029] The features and advantages of the invention involved in this application can be better understood by referring to the exemplary embodiments and drawings described in detail below. A brief description of the drawings is as follows:
[0030] Figure 1 shows a flowchart (Figure A), morphology (Figure B), cell phenotype and yield (Figures C-F) of the iPSC-HPCs 3D differentiation method described in Embodiment 1 of this application. Instruction manual, page 3 / 20, CN 121699861 A
[0031] Figure 2 shows the effects of the small molecule additives CN03 and Endothelin-1 (EDN) described in Example 2 of this application on the phenotype and yield of iPSC-differentiated HPCs. Figures 2A-2B show the effects of adding 250 ng / mL CN03 and 10 ng / mL and 100 ng / mL Edothelin-1 at different time points on the phenotype and yield of iPSC-generated iHPCs. Figures 2C-2D show the effects of adding different concentrations of CN03 at D5-D7 on the phenotype and yield of iPSC-generated iHPCs.
[0032] Figure 3 shows the experimental protocol for further differentiating iHPCs into iT cells described in Example 3 of this application.
[0033] Figure 4 shows the effects of the small molecule additives CN03 and Endothelin-1 (EDN) described in Example 3 of this application on the phenotype (4A), purity (4B), and yield (4C) of iHPCs differentiating into T cell precursors.
[0034] Figure 5 shows the effects of the small molecule additives CN03 and Endothelin-1 (EDN) described in Example 3 of this application on the phenotype (5A) and yield (5B) of iHPCs generating mature iT cells.
[0035] Figure 6 shows the fold increase in the number of iPSCs generating mature iT cells at each stage after adding the small molecule CN03 described in Example 3 of this application.
[0036] Figure 7 shows the scheme (7A) and phenotype (7B) of iHPCs generating NK cells described in Example 4 of this application.Detailed Description of Embodiments
[0037] The embodiments of the present invention are described below by specific examples. Those skilled in the art can easily understand the other advantages and effects of the present invention from the content disclosed in this specification.
[0038] Definition of Terms
[0039] In this application, the term "pluripotent cell" generally refers to a cell with the potential for proliferation and differentiation. Pluripotent cells can be functionally defined as cells that: (1) have the ability to differentiate into different cells and, in some cases, generate only one specialized cell type; (2) can undergo long-term self-renewal to produce one or more cells that are the same as or different from the original cell type. The source and preparation method of pluripotent cells are not limited. For example, the pluripotent cells can be naturally obtained or artificially modified. For example, the pluripotent cells may include induced pluripotent stem cells, hematopoietic stem / progenitor cells, etc.
[0040] In this application, the term "induced pluripotent stem cells" can be abbreviated as "iPS", "iPSC" or "iPSCs", which generally refers to a type of pluripotent stem cells prepared artificially from non-pluripotent cells. Induced pluripotent stem cells can be obtained by introducing specific transcription factors to reprogram terminally differentiated somatic cells. For example, the terminally differentiated cells can be T cells, NK cells, etc.
[0041] In this application, the term "hematopoietic stem / progenitor cells" can be abbreviated as "HPC" or "HPCs," and generally refers to cells with long-term self-renewal capacity and the potential to differentiate into various mature blood cells. The source and preparation method of hematopoietic stem / progenitor cells are not limited; for example, the hematopoietic stem cells can be differentiated from pluripotent cells and can be isolated from bone marrow or blood. Hematopoietic stem cells can differentiate into various cell types, such as bone marrow lineage cells (e.g., monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes / platelets, dendritic cells), and lymphoid lineage cells (e.g., T cells, B cells, NK cells).
[0042] In this application, the terms "Rho activator I / II" and "Rho Activator I / II" can be used interchangeably and are generally used to activate Rho GTPase. The main component of Rho activator II can be CN03 protein. In this application, Rho activator I / II... It can be CN02, CN03, and CN04.
[0043] In this application, the term "T cell" generally refers to a cell with the same or similar phenotype as thymus-derived T cells, which can participate in various cell-mediated immune responses. In this application, the term covers both unmodified T cells and modified T cells.For example, the T cells may be thymocytes, naive T lymphocytes, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, activated T lymphocytes, helper T cells (HTL; CD4+ T cells), cytotoxic T cells (CTL; CD8+ T cells), CD4+CD8+ T cells, CD4-CD8- T cells, and any other subsets of T cells. For example, the T cells may be CAR-T cells and TCR-T cells. In this application, the T cells may be CD5+CD7+ T cell precursors or CD5+CD8αβ+ T cells.
[0044] In this application, the term "modified" generally refers to an alteration in the state or structure of the cells described in this application. Such modification may be artificial or may be caused by environmental conditions resulting in a change compared to the natural source. In this application, the modification can be carried out in various ways known to those skilled in the art, for example, by physical methods, biological methods, chemical methods, etc., to modify the cell structurally and / or functionally. For example, the cell can be modified by introducing nucleic acids. For example, the cell can be modified by genetic engineering. For example, in this application, the T cell can comprise a modified T cell, for example, the modified T cell can be a TCR-T cell or a CAR-T cell. For example, the modified cell can be a pluripotent cell, an induced pluripotent stem cell, or a hematopoietic stem / progenitor cell.
[0045] In this application, the term "composition" generally refers to a product comprising a specified amount of a specified ingredient, and any product produced directly or indirectly from a combination of specified amounts of the specified ingredients. In this application, the composition may also contain other inactive ingredients, such as a carrier, excipient, adjuvant, stabilizer, etc.
[0046] In this application, the term "ex vivo" generally refers to manipulation of cells, tissues, and / or organs that have been removed from a living organism. In some embodiments, the cell, tissue, and / or organ may be returned to the organism or enter another organism by certain methods.
[0047] In this application, the term "in vitro" generally means removing or releasing a part of an organism from the organism.
[0048] In this application, the term "comprising" generally means including, encompassing, containing, or including. In some cases, it also means "as," "consisting of," or "made up of."
[0049] In this application, the term "and / or" should be understood to mean any one, two, or more of the alternatives or any combination thereof.
[0050] In this application, the term "about" generally refers to a variation within a range of 0.5% to 10% above or below a specified value, for example, a variation within a range of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below a specified value.
[0051] Detailed Description of the Invention
[0052] Method
[0053] In one aspect, this application provides a method for proliferating and / or differentiating T cells, comprising the steps of culturing pluripotent cells using Rho activator I / II and proliferating and / or differentiating the pluripotent cells into T cells.
[0054] In this application, the method may further include the process of culturing, proliferating, and / or differentiating pluripotent cells; the method may further include the process of culturing and / or differentiating embryoid bodies (EBs); the method may further include the process of culturing, proliferating, and / or differentiating hematopoietic stem / progenitor cells; the method may further include the process of culturing, proliferating, and / or differentiating induced pluripotent stem cells; the method may further include the process of culturing T cells; the method may further include the process of proliferating and / or differentiating pluripotent cells into embryoid bodies (EBs); the method may further include the process of proliferating and / or differentiating pluripotent cells into hematopoietic stem / progenitor cells; the method may further include the process of differentiating embryoid bodies (EBs) into T cells; the method may further include the process of proliferating and / or differentiating hematopoietic stem / progenitor cells into T cells.
[0055] In this application, the culture method may include culturing cells on a matrix-coated surface. Specification 5 / 20 pages 7 CN 121699861 A
[0056] In some embodiments, the matrix in the culture method may be laminin, vitrin, gelatin, polylysine, thromboretin, or Matrigel™. In some embodiments, the matrix in the culture method may be vitrin or Matrigel™. In some embodiments, the matrix in the culture method may contain DLL4, VCAM, and RetroNectin.
[0057] In this application, the culture method may include periodically or irregularly replenishing and / or replacing the culture medium.
[0058] In this application, the culture method may include digesting the cells into single cells after they have proliferated to a sufficient number.
[0059] In some embodiments, the digestion in the culture method uses Accutase digestion solution. In some embodiments, the digestion in the culture method uses Trypsin and EDTA.
[0060] In this application, the culture method may include culturing cells at approximately 37-39°C, for example, approximately 36.5°C, approximately 37°C, approximately 37.5°C, approximately 38°C, approximately 38.5°C, approximately 39°C, and approximately 39.5°C.
[0061] In this application, the culture method may include culturing cells at approximately 3-7% CO2, for example, approximately 3% CO2, approximately 3.5% CO2, approximately 4% CO2, approximately 4.5% CO2, approximately 5% CO2, approximately 5.5% CO2, approximately 6% CO2, approximately 6.5% CO2, approximately 7% CO2, and approximately 7.5% CO2.
[0062] In this application, the culture method may include culturing cells under hypoxic conditions, which may include about 3-20% O2, for example, about 3% O2, about 3.5% O2, about 4% O2, about 4.5% O2, about 5% O2, about 5.5% O2, about 6% O2, about 6.5% O2, about 7% O2, about 7.5% O2, about 8% O2, about 8.5% O2, about 9% O2, about 9.5% O2, about 10% O2, about 10.5% O2, about 11% O2, about 11.5% O2, about 12% O2, about 12.5% O2, about 13% O2, about 13.5% O2, about 14% O2, about 14.5% O2, about 15% O2, about 15.5% O2, about 16% O2, or about 16.5% O2. O2, approximately 17% O2, approximately 17.5% O2, approximately 18% O2, approximately 18.5% O2, approximately 19% O2, approximately 19.5% O2, approximately 20% O2, approximately 20.5% O2.
[0063] In this application, the culture method can be performed under serum-containing culture conditions. In this application, the culture method can be performed under serum-free culture conditions.
[0064] In this application, the culture method can be performed under culture conditions without feeder cells. In this application, the culture method can be performed under culture conditions with feeder cells.
[0065] In this application, the method can be an in vitro method. In this application, the method can be an ex vivo method.
[0066] In this application, the method can be a method for non-disease diagnosis and treatment purposes.
[0067] In this application, the sources of pluripotent cells, induced pluripotent stem cells and hematopoietic stem / progenitor cells in the culture method are not limited. They can be of mammalian origin or non-mammal origin. They can be derived from human blood in vitro, umbilical cord blood, bone marrow, natural cells or modified cells.
[0068] In this application, the method uses Rho activator I / II, which can activate Rho GTPase. Any natural or synthetic compound that can achieve the same function can be called Rho activator I / II. Rho activator I / II can convert glutamine on Rho GTPase to glutamate through deamination amidation. This chemical modification blocks the GTPase activity of Rho GTPase, thus keeping Rho GTPase in a normally active state. The main component of Rho activator I / II can be CN03 protein.
[0069] In this application, Rho activator I / II can be one or more of CN02, CN03, and CN04. CN02, CN03, and CN04 can be mixed in different proportions. CN02 and CN03 can be mixed in different proportions. CN02 and CN04 can be mixed in different proportions. CN03 and CN04 can be mixed in different proportions. It can be a single component of CN02, CN03, or CN04.
[0070] In this application, the method uses Rho activator I / II. The concentration of Rho activator I / II can be adaptively adjusted according to the cultivation conditions (page 6 / 20, CN 121699861 A) to achieve the best cultivation effect.
[0071] For example, the concentration can be 50-750 ng / mL, 50-700 ng / mL, 50-650 ng / mL, 50-600 ng / mL, 50-550 ng / mL, 50-500 ng / mL, 50-450 ng / mL, 50-400 ng / mL, 50-350 ng / mL, 50-300 ng / mL, 50-250 ng / mL, 50-200 ng / mL, 50-150 ng / mL, 50-100 ng / mL, 50-750 ng / mL, 100-750 ng / mL, 100-700 ng / mL, 100-650 ng / mL, 100-600 ng / mL, 100-550 ng / mL, 100-500 ng / mL, 100-450 ng / mL, 100-400 ng / mL, 100-350 ng / mL, 100-300 ng / mL, 100-250 ng / mL, 100-200 ng / mL, 100-150 ng / mL, 150-750 ng / mL, 150-700 ng / mL, 150-650 ng / mL, 150-600 ng / mL, 150-550 ng / mL, 150-500 ng / mL, 150-450 ng / mL, 150-400 ng / mL, 150-350 ng / mL, 150-300 ng / mL, 150-250 ng / mL, 150-200 ng / mL, 200-750 ng / mL, 200-700 ng / mL, 200-650 ng / mL, 200-600 ng / mL, 200-550 ng / mL, 200-500 ng / mL, 200-450 ng / mL, 200-400 ng / mL, 200-350 ng / mL, 200-300 ng / mL, 200-250 ng / mL, about 50 ng / mL, about 100 ng / mL, about 150 ng / mL, about 200 ng / mL, about 250 ng / mL, about 300 ng / mL, about 350 ng / mL, about 400 ng / mL, about 450 ng / mL, about 500 ng / mL, about 550 ng / mL, about 600 ng / mL, about 650 ng / mL, about 700 ng / mL, approximately 750 ng / mL.
[0072] In this application, the time for culturing pluripotent cells using Rho activator I / II can be adaptively adjusted according to different cells and culture conditions to achieve the best culture effect.
[0073] For example, the culture time can be 12-96 hours, 12-84 hours, 12-72 hours, 12-60 hours, 12-48 hours, 12-36 hours, 12-24 hours, 24-96 hours, 24-84 hours, 24-72 hours, 24-60 hours, 24-48 hours, 24-36 hours, 36-96 hours, 36-84 hours, 36-72 hours, 36-60 hours, 36-48 hours, 48-96 hours, 48-84 hours, 48-72 hours, 48-60 hours, approximately 12 hours, approximately 24 hours, approximately 36 hours, approximately 48 hours, approximately 60 hours, approximately 72 hours, approximately 84 hours, approximately 96 hours.
[0074] In this application, the method can use CNO3, and the concentration of CNO3 can be adaptively adjusted according to the culture conditions to achieve the best culture effect.
[0075] For example, the concentration can be 50-750 ng / mL, 50-700 ng / mL, 50-650 ng / mL, 50-600 ng / mL, 50-550 ng / mL, 50-500 ng / mL, 50-450 ng / mL, 50-400 ng / mL, 50-350 ng / mL, 50-300 ng / mL, 50-250 ng / mL, 50-200 ng / mL, 50-150 ng / mL, 50-100 ng / mL, 50-750 ng / mL, 100-750 ng / mL, 100-700 ng / mL, 100-650 ng / mL, 100-600 ng / mL, 100-550 ng / mL, 100-500 ng / mL, 100-450 ng / mL, 100-400 ng / mL, 100-350 ng / mL, 100-300 ng / mL, 100-250 ng / mL, 100-200 ng / mL, 100-150 ng / mL, 150-750 ng / mL, 150-700 ng / mL, 150-650 ng / mL, 150-600 ng / mL, 150-550 ng / mL, 150-500 ng / mL, 150-450 ng / mL, 150-400 ng / mL, 150-350 ng / mL, 150-300 ng / mL, 150-250 ng / mL, 150-200 ng / mL, 200-750 ng / mL, 200-700 ng / mL, 200-650 ng / mL, 200-600 ng / mL, 200-550 ng / mL, 200-500 ng / mL, 200-450 ng / mL, 200-400 ng / mL, 200-350 ng / mL, 200-300 ng / mL, 200-250 ng / mL, about 50 ng / mL, about 100 ng / mL, about 150 ng / mL, about 200 ng / mL, about 250 ng / mL, about 300 ng / mL, about 350 ng / mL, about 400 ng / mL, about 450 ng / mL, about 500 ng / mL, about 550 ng / mL, about 600 ng / mL, about 650 ng / mL, about 700 ng / mL, approximately 750 ng / mL.
[0076] In this application, the time for culturing pluripotent cells using CN03 can be adaptively adjusted according to different cells and culture conditions to achieve the best culture effect.
[0077] For example, the culture time can be 12-96 hours, 12-84 hours, 12-72 hours, 12-60 hours, 12-48 hours, 12-36 hours, 12-24 hours, 24-96 hours, 24-84 hours, 24-72 hours, 24-60 hours, 24-48 hours, 24-36 hours, 36-96 hours, 36-84 hours, 36-72 hours, 36-60 hours, 36-48 hours, 48-96 hours, 48-84 hours, 48-72 hours, 48-60 hours, about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, about 72 hours, about 84 hours, about 96 hours.
[0078] In this application, the T cells include T cells with different phenotypes, which may be modified T cells or unmodified T cells. For example, the T cells may be thymocytes, naive T lymphocytes, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, activated T lymphocytes, helper T cells (HTL; CD4+ T cells), cytotoxic T cells (CTL; CD8+ T cells), CD4+CD8+ T cells, CD4-CD8- T cells, and any other subsets of T cells. For example, the T cells may be CAR-T cells and TCR-T cells. For example, the T cells may be CD5+CD7+ T cell precursors or CD5+CD8αβ+ T cells.
[0079] In this application, the method includes culturing pluripotent cells using a culture medium.
[0080] In this application, the culture medium may contain a basal culture medium. For example, the basal culture medium may contain any culture medium known in the art. For example, the basal culture medium may contain one or more of IMDM, MEM, Ham's F12, mTeSR1, APEL, StemSpan™ SFEM II, DMEM, Nuwacell® ncTarget complete medium, Stempro-34 complete medium, and RPMI 1640. For example, the basal culture medium may be Nuwacell® ncTarget complete medium. For example, the basal culture medium may be StemSpan™ SFEM II. For example, the basal culture medium may be Stempro-34 complete medium.
[0081] In this application, the culture medium may contain one or more of nutrients, extracts, growth factors, hormones, cytokines, and culture medium additives. The types and concentrations of added components can be adaptively adjusted according to the culture conditions to achieve better culture results.
[0082] For example, one or more of the following components may be added: serum substitutes, glutamine, NEAA (non-essential amino acids), ascorbic acid, epidermal growth factor (EGF), acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), leukemia inhibitory factor (LIF), hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), insulin-like growth factor 2 (IGF-2), keratinocyte growth factor (KGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), transforming growth factor β (TGF-β), bone morphogenetic protein (BMP4), vascular endothelial growth factor (VEGF), transferrin, insulin, selenium, various interleukins (e.g., IL-1 to IL-18), various colony-stimulating factors (e.g., granulocyte / macrophage colony-stimulating factor (GM-CSF)), and various interferons (e.g., IFN-γ). γ), stem cell factor (SCF), thrombopoietin (TPO), erythropoietin (EPO), N2 additive, B27 additive, Fms-associated tyrosine kinase 3 ligand (FLt3). The additives are not limited to any particular source and can be commercially available, natural, or recombinant.
[0083] For example, one or more of the following components may be added: CHIR99021, Y-27632, GlutaMAX, L-ascorbic acid, MTG, ITS, BMP4, VEGF, bFGF, SB 431542, SCF, TPO, FLT3, Sodium Pyruvate, β-Mercaptoethanol, NEAA, IL-7, IL-15, SB203580, SDF-1α, Dexamethasone, IL-21, and Anti-CD3 (OKT3).
[0084] Culture Medium
[0085] On the other hand, this application provides a culture medium for culturing pluripotent cells and differentiating them into T cells, the culture medium containing Rho activator I / II.
[0086] In this application, Rho activator II can activate Rho GTPase, and any natural or synthetic compound that can achieve the same function can be called Rho activator I / II. Rho activator I / II can convert glutamine on Rho GTPase to glutamate through deamination amidation, and this chemical modification leads to the blocking of the GTPase activity of Rho GTPase, thereby keeping Rho GTPase in a normal active state.The main component of Rho activator I / II can be CN03 protein (see page 8 / 20 of the instruction manual, CN 121699861 A).
[0087] In this application, Rho activator I / II can be one or more of CN02, CN03 and CN04. CN02, CN03 and CN04 can be mixed in different proportions, CN02 and CN03 can be mixed in different proportions, CN02 and CN04 can be mixed in different proportions, CN03 and CN04 can be mixed in different proportions, or it can be a single component of CN02, CN03, or CN04.
[0088] In this application, the concentration of Rho activator I / II can be adaptively adjusted according to the culture conditions to achieve the best culture effect.
[0089] For example, the concentration may be 50‑750 ng / mL, 50‑700 ng / mL, 50‑650 ng / mL, 50‑600 ng / mL, 50‑550 ng / mL, 50‑500 ng / mL, 50‑450 ng / mL, 50‑400 ng / mL, 50‑350 ng / mL, 50‑300 ng / mL, 50‑250 ng / mL, 50‑200 ng / mL, 50‑150 ng / mL, 50‑100 ng / mL, 50‑750 ng / mL, 100‑750 ng / mL, 100‑700 ng / mL, 100‑650 ng / mL, 100‑600 ng / mL, 100‑550 ng / mL, 100‑500 ng / mL, 100‑450 ng / mL, 100‑400 ng / mL, 100‑350 ng / mL, 100‑300 ng / mL, 100‑250 ng / mL, 100‑200 ng / mL, 100‑150 ng / mL, 150‑750 ng / mL, 150‑700 ng / mL, 150‑650 ng / mL, 150‑600 ng / mL, 150‑550 ng / mL, 150‑500 ng / mL, 150‑450 ng / mL, 150‑400 ng / mL, 150‑350 ng / mL, 150‑300 ng / mL, 150‑250 ng / mL, 150‑200 ng / mL, 200‑750 ng / mL, 200‑700 ng / mL, 200‑650 ng / mL, 200‑600 ng / mL, 200‑550 ng / mL, 200‑500 ng / mL, 200‑450 ng / mL, 200‑400 ng / mL, 200‑350 ng / mL, 200‑300 ng / mL, 200‑250 ng / mL, about 50 ng / mL, about 100 ng / mL, about 150 ng / mL, about 200 ng / mL, about 250 ng / mL, about 300 ng / mL, about 350 ng / mL, about 400 ng / mL, about 450 ng / mL, about 500 ng / mL, about 550 ng / mL, about 600 ng / mL, about 650 ng / mL, about 700 ng / mL, or about 750 ng / mL.
[0090] In the present application, the Rho activator I / II may be CN03, and the concentration of said CN03 can be adaptively adjusted according to the culture conditions, so as to achieve the best culture effect.
[0091] For example, the concentration may be 50‑750 ng / mL, 50‑700 ng / mL, 50‑650 ng / mL, 50‑600 ng / mL, 50‑550 ng / mL, 50‑500 ng / mL, 50‑450 ng / mL, 50‑400 ng / mL, 50‑350 ng / mL, 50‑300 ng / mL, 50‑250 ng / mL, 50‑200 ng / mL, 50‑150 ng / mL, 50‑100 ng / mL, 50‑750 ng / mL, 100‑750 ng / mL, 100‑700 ng / mL, 100‑650 ng / mL, 100‑600 ng / mL, 100‑550 ng / mL, 100‑500 ng / mL, 100‑450 ng / mL, 100‑400 ng / mL, 100‑350 ng / mL, 100‑300 ng / mL, 100‑250 ng / mL, 100‑200 ng / mL, 100‑150 ng / mL, 150‑750 ng / mL, 150‑700 ng / mL, 150‑650 ng / mL, 150‑600 ng / mL, 150‑550 ng / mL, 150‑500 ng / mL, 150‑450 ng / mL, 150‑400 ng / mL, 150‑350 ng / mL, 150‑300 ng / mL, 150‑250 ng / mL, 150‑200 ng / mL, 200‑750 ng / mL, 200‑700 ng / mL, 200‑650 ng / mL, 200‑600 ng / mL, 200‑550 ng / mL, 200‑500 ng / mL, 200‑450 ng / mL, 200‑400 ng / mL, 200‑350 ng / mL, 200‑300 ng / mL, 200‑250 ng / mL, about 50 ng / mL, about 100 ng / mL, about 150 ng / mL, about 200 ng / mL, about 250 ng / mL, about 300 ng / mL, about 350 ng / mL, about 400 ng / mL, about 450 ng / mL, about 500 ng / mL, about 550 ng / mL, about 600 ng / mL, about 650 ng / mL, about 700 ng / mL, or about 750 ng / mL.
[0092] In the present application, the culture medium may comprise a basal medium. For example, the basal medium may comprise any medium known in the art.For example, the basal culture medium may contain one or more of IMDM, MEM, Ham's F12, mTeSR1, APEL, StemSpan™ SFEM II, DMEM, Nuwacell® ncTarget complete medium, Stempro-34 complete medium, and RPMI1640. For example, the basal culture medium may be Nuwacell® ncTarget complete medium. For example, the basal culture medium may be StemSpan™ SFEM II. For example, the basal culture medium may be Stempro-34 complete medium. Specification 9 / 20 pages 11 CN 121699861 A
[0093] In this application, the culture medium may contain one or more of nutrients, extracts, growth factors, hormones, cytokines, and culture medium additives. The types and concentrations of added components can be adaptively adjusted according to the culture conditions to achieve better culture results.
[0094] For example, one or more of the following components may be added: serum substitutes, glutamine, NEAA (non-essential amino acids), ascorbic acid, epidermal growth factor (EGF), acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), leukemia inhibitory factor (LIF), hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), insulin-like growth factor 2 (IGF-2), keratinocyte growth factor (KGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), transforming growth factor β (TGF-β), bone morphogenetic protein (BMP4), vascular endothelial growth factor (VEGF), transferrin, insulin, selenium, various interleukins (e.g., IL-1 to IL-18), various colony-stimulating factors (e.g., granulocyte / macrophage colony-stimulating factor (GM-CSF)), and various interferons (e.g., IFN-γ). γ), stem cell factor (SCF), thrombopoietin (TPO), erythropoietin (EPO), N2 additive, B27 additive, and Fms-associated tyrosine kinase 3 ligand (FLT3). The additives are not limited in origin and can be commercially available, natural, or recombinant.
[0095] For example, one or more of the following components may be added: CHIR99021, Y-27632, GlutaMAX, L-ascorbic acid, MTG, ITS, BMP4, VEGF, bFGF, SB 431542, SCF, TPO, FLT3, Sodium Pyruvate, β-Mercaptoethanol, NEAA, IL-7, IL-15, SB203580, SDF-1α, Dexamethasone, and Anti-CD3 (OKT3).
[0096] Compositions and Uses
[0097] On the other hand, this application provides a composition comprising pluripotent cells and the culture medium described in this application.
[0098] On the other hand, this application provides a composition comprising induced pluripotent stem cells and the culture medium described in this application.
[0099] On the other hand, this application provides a composition comprising hematopoietic stem / progenitor cells and the culture medium described in this application.
[0100] On the other hand, this application also provides a culture platform for obtaining T cells, comprising the method and the culture medium.
[0101] On the other hand, this application also provides a method for preventing and / or treating a disease, comprising administering T cells to a subject in need, the T cells being obtained by using the method, the culture medium, the composition, and the culture platform.
[0102] For example, the administered T cells can be pharmaceutically formulated according to any conventional method. For example, a carrier, excipient, or diluent can be used to mix or dilute the active ingredient. Examples of suitable carriers, excipients, or diluents are lactose, dextrose, sucrose, sorbitol, mannitol, glycine, polyethylene glycol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylparaben, propylparaben, talc, magnesium stearate, and mineral oil. The formulation may additionally include, for example, fillers, anticoagulants, lubricants, wetting agents, flavoring agents, emulsifiers, preservatives, etc. The compositions of the present invention are formulated using any method known in the art to provide a rapid, sustained, or delayed release of the active ingredient upon administration to a patient.
[0103] In this application, the cells can be administered by injection (e.g., intramuscular, intravenous, intraperitoneal, subcutaneous) or by other methods such as infusion to ensure that they enter the bloodstream in an effective form. The cells can also be administered via intratumoral, peritumoral, intralesional, or perilesional routes to exert local and systemic therapeutic effects. For example, they can be administered by local or intravenous injection. Specification 10 / 20 pages 12 CN 121699861 A
[0104] In this application, the dosage of the cells can also be a single dose or multiple doses.For example, the actual amount of cells administered can be determined based on various relevant factors, such as the type of disease; the route of administration; the patient's age, sex, and / or weight; and the severity of the patient's symptoms.
[0105] This application also provides the following embodiments:
[0106] 1. A method for proliferating and / or differentiating T cells, comprising culturing pluripotent cells using Rho activator I / II and proliferating and / or differentiating the pluripotent cells into T cells.
[0107] 2. The method according to embodiment 1, wherein the pluripotent cells are induced pluripotent stem cells (iPSCs).
[0108] 3. The method according to embodiment 1, wherein the pluripotent cells are hematopoietic stem / progenitor cells (HPCs).
[0109] 4. The method according to any one of embodiments 1-3, wherein the pluripotent cells are modified cells.
[0110] 5. The method according to any one of embodiments 1-4, wherein the Rho activator I / II is selected from one or more activators of the group consisting of CN02, CN03, and CN04.
[0111] 6. The method according to any one of Embodiments 1-5, wherein the Rho activator II is CN02.
[0112] 7. The method according to any one of Embodiments 1-6, wherein the Rho activator II is CN03.
[0113] 8. The method according to any one of Embodiments 1-7, wherein the Rho activator I is CN04.
[0114] 9. The method according to any one of Embodiments 1-8, wherein the method comprises culturing pluripotent cells using Rho activator I / II for a culture time of 12-96 hours.
[0115] 10. The method according to any one of Embodiments 1-9, wherein the method comprises culturing pluripotent cells using Rho activator I / II for a culture time of 12-72 hours.
[0116] 11. The method according to any one of Embodiments 1-10, wherein the method comprises culturing pluripotent cells using Rho activator I / II for a culture time of 12-48 hours.
[0117] 12. The method according to any one of Embodiments 1-11, wherein the method comprises culturing pluripotent cells using Rho activator I / II for 24-48 hours.
[0118] 13. The method according to any one of Embodiments 1-12, wherein the method comprises culturing pluripotent cells using CNO3 for about 48 hours.
[0119] 14. The method according to any one of Embodiments 11-13, wherein the concentration of Rho activator I / II is 50-750 ng / mL.
[0120] 15. The method according to any one of Embodiments 1-14, wherein the concentration of Rho activator I / II is 150-350 ng / mL.
[0121] 16. The method according to any one of Embodiments 1-15, wherein the concentration of Rho activator I / II is about 250 ng / mL.
[0122] 17. The method according to any one of Embodiments 5-16, wherein the concentration of CNO3 is 50-750 ng / mL.
[0123] 18. The method according to any one of Embodiments 5-17, wherein the concentration of CNO3 is 150-350 ng / mL.
[0124] 19. The method according to any one of Embodiments 5-18, wherein the concentration of CNO3 is about 250 ng / mL.
[0125] 20. The method according to any one of Embodiments 1-19, wherein the T cells are CD5+CD7+ T precursor cells.
[0126] 21. The method according to any one of Embodiments 1-20, wherein the T cells are CD5+CD8αβ+ T cells. Instruction manual, pages 11 / 20, 13 CN 121699861 A
[0127] 22. The method according to any one of embodiments 1-21, wherein the method includes culturing cells under hypoxic conditions.
[0128] 23. The method according to any one of embodiments 1-22, wherein the hypoxic condition is 5% O2.
[0129] 24. The method according to any one of embodiments 1-23, wherein the method includes culturing cells under serum-free culture conditions.
[0130] 25. The method according to any one of embodiments 1-24, wherein the method does not use feeder cells.
[0131] 26. The method according to any one of embodiments 1-25, wherein the method comprises culturing pluripotent cells using a culture medium comprising one or more of the following factors: CHIR99021, Y-27632, GlutaMAX, L-ascorbic acid, MTG, ITS, BMP4, VEGF, bFGF, SB 431542, SCF, TPO, FLT3, Sodium Pyruvate, β-Mercaptoethanol, NEAA, IL-7, IL-15, SB203580, SDF-1α, Dexamethasone, IL-21, and Anti-CD3 OKT3.
[0132] 27. The method according to any one of embodiments 1-26, wherein the method comprises culturing pluripotent cells using a culture medium comprising a basal culture medium.
[0133] 28. The method according to any one of Embodiments 1-27, wherein the basal culture medium is selected from one or more of the following culture media: Nuwacell® ncTarget complete medium, Stempro-34 complete medium, and StemSpan SFEM II medium.
[0134] 29. A culture medium for culturing pluripotent cells and differentiating pluripotent cells into T cells, wherein the culture medium contains Rho activator I / II.
[0135] 30. The culture medium according to Embodiment 29, wherein the pluripotent cells are induced pluripotent stem cells (iPSCs).
[0136] 31. The culture medium according to Embodiment 29, wherein the pluripotent cells are hematopoietic stem / progenitor cells (HPCs).
[0137] 32. The culture medium according to any one of Embodiments 29-31, wherein the pluripotent cells are modified cells.
[0138] 33. The culture medium according to any one of Embodiments 29-32, wherein the Rho activator I / II is selected from one or more of the following activators: CNO2, CNO3, and CNO4.
[0139] 34. The culture medium according to any one of Embodiments 29-33, wherein the Rho activator II is CN02.
[0140] 35. The culture medium according to any one of Embodiments 29-34, wherein the Rho activator II is CN03.
[0141] 36. The culture medium according to any one of Embodiments 29-35, wherein the Rho activator I is CN04.
[0142] 37. The culture medium according to any one of Embodiments 29-36, wherein the concentration of Rho activator I / II is 50-750 ng / mL.
[0143] 38. The culture medium according to any one of Embodiments 29-37, wherein the concentration of Rho activator I / II is 150-350 ng / mL.
[0144] 39. The culture medium according to any one of Embodiments 29-38, wherein the concentration of Rho activator I / II is about 250 ng / mL.
[0145] 40. The culture medium according to any one of Embodiments 33-39, wherein the concentration of CNO3 is 50-750 ng / mL.
[0146] 41. The culture medium according to any one of Embodiments 33-40, wherein the concentration of CNO3 is 150-350 ng / mL.
[0147] 42. The culture medium according to any one of Embodiments 33-41, wherein the concentration of CNO3 is about 250 ng / mL.Instruction manual 12 / 20 pages 14 CN 121699861 A
[0148] 43. The culture medium according to any one of embodiments 29-42, wherein the T cells are CD5+CD7+ T precursor cells.
[0149] 44. The culture medium according to any one of embodiments 29-43, wherein the T cells are CD5+CD8αβ+ T cells.
[0150] 45. The culture medium according to any one of embodiments 29-44, comprising one or more of the following factors: CHIR99021, Y-27632, GlutaMAX, L-ascorbic acid, MTG, ITS, BMP4, VEGF, bFGF, SB 431542, SCF, TPO, FLT3, Sodium Pyruvate, β-Mercaptoethanol, NEAA, IL-7, IL-15, SB203580, SDF-1α, Dexamethasone, IL-21, and Anti-CD3 OKT3.
[0151] 46. The culture medium according to any one of embodiments 29-45, comprising a basal culture medium.
[0152] 47. The culture medium according to any one of embodiments 29-46, wherein the basal culture medium is selected from one or more of the following culture media: Nuwacell® ncTarget complete medium, Stempro-34 complete medium, and StemSpan SFEM II medium.
[0153] 48. A composition comprising pluripotent cells and the culture medium described in any one of embodiments 29-47.
[0154] 49. A culture platform for obtaining T cells comprising the method described in any one of embodiments 1-28 and / or the culture medium described in any one of embodiments 29-47.
[0155] 50. Application of the culture platform described in embodiment 49 comprising the method described in any one of embodiments 1-28 and / or the culture medium described in any one of embodiments 29-47.
[0156] Not intended to be limited by any theory, the examples below are merely for illustrating the preparation methods and uses of this application, and are not intended to limit the scope of the invention.
[0157] Examples
[0158] Example 1 A method for inducing iPSCs to generate hematopoietic stem / progenitor cells in 3D differentiation
[0159] 1) When the iPSCs reach approximately 80% confluence, they are transferred from the incubator to a biosafety cabinet, and the culture medium is discarded. The bottom of the culture flask is rinsed with DPBS (without calcium and magnesium ions), and then the DPBS is discarded. Add an appropriate amount of Accutase (1 mL / 10 cm²) to a six-well plate and shake to thoroughly wet the bottom. Then transfer the six-well plate to a 37°C incubator for digestion.
[0160] 2) After digestion until the cells detach from the bottom of the culture plate, digestion is terminated using Nuwacell® ncTarget medium. After centrifugation, the supernatant is removed, and the cells are fully resuspended in Nuwacell® ncTarget medium and filtered through a 40 μM sieve. AO / PI sampling and counting are performed. Cells are seeded into low-adsorption six-well plates (small system) or conical culture flasks (large system) at a density of 0.6 x 10e6 / mL. The six-well plates are transferred to a horizontal shaker in a hypoxic incubator (5% O2) at a shaking speed of 80 rpm. This is iPSC-HPC differentiation day D0.
[0161] Table 1. Culture medium composition (D0)
[0162]
[0163] 3) On differentiation day D1, the six-well plates are left to stand for 5 minutes until the EB beads sink to the bottom. The supernatant, which accounts for more than 85% of the total volume, is gently aspirated into a 15 mL centrifuge tube and centrifuged. After centrifugation, remove the supernatant and resuspend the cells in 2 mL of differentiation medium (D1). Transfer the cell suspension to a six-well plate. Transfer the six-well plate to a horizontal shaker in a hypoxic incubator (5% O2) and culture at 80 rpm.
[0164] Table 2. Culture medium composition (D1)
[0165]
[0166] 4) On differentiation day D2, let the six-well plate stand for 5 minutes until the EB balls sink to the bottom. Gently aspirate 85% of the total volume of supernatant and add fresh differentiation medium (D2-D3) to the six-well plate. Transfer the six-well plate to a horizontal shaker in a hypoxic incubator and culture at 80 rpm. Culture time: 24 hours.
[0167] 5) On differentiation day D3, let the six-well plate stand for 5 minutes until the EB beads sink to the bottom. Gently aspirate 85% of the total volume of supernatant and add fresh differentiation medium (D2-D3) to the six-well plate. Transfer the six-well plate to a horizontal shaker in a hypoxic incubator and culture at 80 rpm. Culture time: 24 hours.
[0168] Table 3. Culture medium composition (D2-D3)
[0169]
[0170] 6) On differentiation day D4, let the six-well plate stand for 5 minutes until the EB beads sink to the bottom. Gently aspirate 85% of the total volume of supernatant (if suspended cells are present, the supernatant needs to be removed after centrifugation), and add fresh differentiation medium (D4-D6) to the six-well plate. Transfer the six-well plate to a horizontal shaker in a normoxic incubator and culture at 80 rpm. Culture time: 24 hours. After that, change the solution on page 14 / 20 of the instruction manual, 16 CN 121699861 A once a day, following the same steps as above.
[0171] Table 4. Culture medium composition (D4-D6)
[0172]
[0173] 7) Differentiation D7-D14 days, let the six-well plate stand for 5 minutes until the EB balls sink to the bottom.Gently aspirate 85% of the total volume of supernatant (if suspended cells are present, the supernatant needs to be removed after centrifugation), and add fresh differentiation medium (D7-D14) to the six-well plate. Transfer the six-well plate to a horizontal shaker in a normoxic incubator and culture at 80 rpm. Culture time is 24 hours. Change the medium once a day thereafter, following the same steps.
[0174] Table 5. Culture medium composition (D7-D14)
[0175]
[0176] 8) On day 14 of differentiation, collect the suspended cells and detect the HPC purity by flow cytometry. Instruction manual, pages 15 / 20, 17 CN 121699861 A
[0177] The above experiments show that:
[0178] As shown in Figure 1, the method listed in Example 1 does not require serum or feeder cells throughout the entire process. iPSCs are cultured in a conical flask / six-well plate on a shaker at 80 rpm to spontaneously form EB spheres. The spheres are uniform in size, the operation is simple, and it is easy to scale up for use on a large scale. The generated hematopoietic stem cells are gradually released into the suspension system, which is easy to collect and does not require digestion of EB spheres. The expansion factor is between 5 and 10 times. The generated CD45+CD34+CD38-CD235a- cells have high purity and can be directly used for the next step of cell differentiation or library construction without the need for flow cytometry or magnetic bead sorting.
[0179] Example 2 Inducing iPSC to Generate Hematopoietic Stem / Progenitor Cells by Adding Small Molecule Compounds
[0180] To test the function of small molecule additives in iPSC-HPC differentiation, in the iPSC differentiation method used in Example 1, different concentrations of CNO3 and Endothelin-1 were added at different time points from D5 to D14 to test the HPC production rate.
[0181] 1) CNO3 was added at a concentration of 250 ng / mL at differentiation points D5-D7, D7-D9, and D5-D9, respectively. In addition, at differentiation points D5-D7, the concentrations were 50 ng / mL, 150 ng / mL, 250 ng / mL, 350 ng / mL, 750 ng / mL, and 1000 ng / mL, respectively, to test the HPC phenotype and production rate.
[0182] 2) Endothelin-1 was added at concentrations of 10 ng / mL and 100 ng / mL during differentiation at D5-D9 and D8-D14, respectively.
[0183] The above experiments show that:
[0184] 1) CNO3: As shown in Figure 2, the addition of 250 ng / mL CNO3 on Day 5-Day 7 significantly increased the HPC yield (approximately 4 times the yield), and on Day 7-Day 9 it increased the HPC yield (approximately 2 times the yield), but the addition on Day 5-9 had no effect on the yield.When different concentrations of CN03 were added on Day 5-Day 7, 150 ng / mL-350 ng / mL all increased the yield, with 250 ng / mL CN03 increasing the yield by about 4-5 times compared to the control group. However, 50 ng / mL did not significantly increase the yield, while 750 ng / mL and 1000 ng / mL significantly reduced the yield and affected the phenotype. Therefore, when CN03 was added at 250 ng / mL on Day 5-Day 7, it could maximize the HPC yield.
[0185] 2) Endothelin-1: As shown in Figure 2, when Endothelin-1 was added at concentrations of 100 ng / mL and 10 ng / mL on Day 5-9 and Day 8-14, it only increased the HPC yield by a maximum of about 1.5 times.
[0186] Example 3: HPCs generated by iPSCs differentiate into T cells
[0187] 1) Early T cell differentiation (D0-D14): Prepare “DVR” coating solution diluted with PBS (8 μg / mL VCAM-1 + 20 μg / mL DLL4 + 10 μg / mL RetroNectine), and coat at room temperature for 2 hours or overnight at 4°C. Take the suspension cells from Examples 1 and 2 on day 14 of differentiation, seed about 10,000 HPCs cells in each well of a 24-well plate, and add T cell differentiation medium. Add fresh medium after three days, and then perform half medium replacement every three days thereafter. On day 14 of differentiation, collect the cells into a 15 mL centrifuge tube, wash once with PBS, centrifuge at room temperature, discard the supernatant, add an appropriate amount of differentiation medium to resuspend, gently mix, and then aspirate the cell suspension and mix with AO / PI staining solution 1:1 for cell counting. Take an appropriate amount of cell suspension for flow cytometry phenotyping analysis of the proportion and phenotype of T cell precursors (CD5, CD7, CD8a, CD56).
[0188] Table 6. T cell differentiation medium composition instructions 16 / 20 pages 18 CN 121699861 A
[0189]
[0190] 2) Late T cell differentiation (D14-D21): Prepare a solution containing 1 μg / mL DLL4 and 10 μg / mL RetroNectine in PBS to coat the cell culture plate (coat at room temperature for 2 hours or overnight at 4°C, then dilute with PBS). Seed 500,000 T cells on day 14 of differentiation in each well with T differentiation medium. After 3 days, add twice the amount of T differentiation medium to each well, and then perform half medium replacement every 3 days. On day 21 of differentiation: collect cells into 15 mL centrifuge tubes, centrifuge at room temperature, discard the supernatant, add medium to resuspend, gently mix, and then take 20 μl of cell suspension and 20 μl of AO / PI staining solution for cell counting. Take an appropriate amount of cell suspension for flow cytometry phenotypic analysis of T cell expression.
[0191] 3) T cell maturation: Prepare a solution containing 1 μg / mL DLL4 and 10 μg / mL RetroNectine using PBS, coat the cell culture plate, and incubate at room temperature for two hours or overnight at 4°C. Wash once with PBS before use. T cells on day 21 of differentiation are resuspended in Maturation medium 1 and transferred to well plates, and cultured at 37°C for 3 days. Prepare RetroNectine dilution with PBS, coat the culture plate at room temperature for 2 hours or overnight at 4°C, and wash once with PBS before use. Collect cells on day 3 of maturation, centrifuge to remove supernatant, add Maturation medium 2 to resuspend, and transfer to well plates coated with RetroNectine. After culturing at 37°C for 4 days, collect cells, and take an appropriate amount of cell suspension for flow cytometry phenotypic analysis of CD4 / CD8a / CD8b / CD5.
[0192] Table 7. Maturation medium composition instructions 17 / 20 pages 19 CN 121699861 A
[0193]
[0194] 4) Amplification capacity test: HPCs obtained by the optimized method of iPSCs listed in Examples 2 and 3, after further differentiation into T cells and induction of maturation, can achieve an amplification of about 400,000 times from iPSCs to T cells after two rounds of amplification using anti-CD3 antibody.
[0195] The above experimental results show that:
[0196] 1) As shown in Figures 4 and 5, HPCs obtained by the 3D differentiation method of iPSCs listed in Examples 1 and 2 can efficiently generate CD5+CD7+ T precursor cells and CD5+CD8αβ+ T cells with typical characteristics. The whole process does not require serum and feeder cells, and is safe and controllable.
[0197] 2) As shown in Figure 4, the addition of the small molecule compound CN03 (250 ng / mL, Day 5-7) during the iPSC-to-HPCs generation stage increased the proportion of CD5+CD7+ T cell precursors in the early differentiation process of the generated HPCs and significantly improved the yield of T cell precursor cells.
[0198] 3) As shown in Figure 5, the addition of CN03 during the iPSC-to-HPCs generation stage from Day 5 to Day 7 significantly improved the yield of HPCs subsequently generating mature iT cells. The addition of the small molecule compound Endothelin-1 had no effect.
[0199] 4) As shown in Figure 6, the iT cells obtained by the differentiation method used in this patent can be expanded with high efficiency. After two rounds of expansion, the iT cells generated by each iPSC can achieve an expansion efficiency of approximately 400,000 times.
[0200] Example 4: HPCs generated from iPSCs differentiated into NK cells
[0201] On day 14 of differentiation of the iHPCs in Example 1, all suspended cells and EB spheres were collected by centrifugation. The cells were resuspended to 2 million / mL using NK differentiation medium 1 as listed below. The culture vessel was transferred to a horizontal shaker in a 5% CO2 incubator at 80 rpm. The supernatant was removed by centrifugation every two days and the culture medium was replaced with fresh medium. NK differentiation medium 1 was used for the first 7 days, and the cell density was adjusted to 2 million / mL. NK differentiation medium 2 was used for the next 7 days, and the cell density was adjusted to 3 million / mL. On day 14 of NK differentiation, all cells were collected, counted, and flow cytometry was used to detect CD94 / CD56 / CD16 / NKG2A. Instruction manual 18 / 20 pages 20 CN 121699861 A
[0202] Table 8. NK differentiation medium 1
[0203]
[0204] Table 9. NK differentiation medium 2
[0205]
[0206] The above experimental results show that:
[0207] As shown in Figure 7, the method for differentiating iPSCs into HPCs listed in Example 1 can further differentiate into NK cells with high efficiency in a culture system without a feeder layer and in suspension, with a ratio as high as 50%-80%, and each iPSC cell can differentiate into 5000-10000 NK cells.Instruction Manual 20 / 20 Page 22 CN 121699861 A Figure 1A Figure 1B Figure 1C Instruction Manual Drawings 1 / 11 Page 23 CN 121699861 A Figure 1D Figure 1E Instruction Manual Drawings 2 / 11 Page 24 CN 121699861 A Figure 1F Instruction Manual Drawings 3 / 11 Page 25 CN 121699861 A Figure 2A Instruction Manual Drawings 4 / 11 Page 26 CN 121699861 A Figure 2B Figure 2C Instruction Manual Drawings 5 / 11 Page 27 CN 121699861 A Figure 2D Figure 3 Instruction Manual Drawings 6 / 11 Page 28 CN 121699861 A Figure 4A Instruction Manual Drawings 7 / 11 Page 29 CN 121699861 A Figure 4B Figure 4C Instruction Manual Drawings 8 / 11 Page 30 CN 121699861 A Figure 5A Instruction Manual Figures 9 / 11, Page 31, CN 121699861 A, Figure 5B, Figure 6; Instruction Manual Figures 10 / 11, Page 32, CN 121699861 A, Figure 7A, Figure 7B; Instruction Manual Figures 11 / 11, Page 33, CN 121699861 A. Abstract: This application relates to a method for proliferating and / or differentiating T cells, which comprises culturing pluripotent cells with Rho activators I / II, and proliferating and / or differentiating the pluripotent cells into T cells. This application also provides culture media, culture platforms, and applications for culturing pluripotent cells and proliferating and / or differentiating them into T cells.
Claims
1. A method for proliferating and / or differentiating T cells, comprising culturing pluripotent cells using Rho activator I / II and proliferating and / or differentiating the pluripotent cells into T cells.
2. The method according to claim 1, wherein the Rho activator I / II is selected from one or more activators of the group consisting of CN02, CN03 and CN04.
3. The method according to any one of claims 1-2, wherein the method comprises culturing pluripotent cells using Rho activator I / II for 24-48 hours.
4. The method according to any one of claims 1-3, wherein the concentration of the Rho activator I / II is 150-350 ng / mL.
5. The method according to any one of claims 1-4, wherein the method comprises culturing cells under hypoxic conditions.
6. The method according to any one of claims 1-5, wherein the method comprises culturing pluripotent cells using a culture medium containing one or more of the following factors: CHIR99021, Y-27632, GlutaMAX, L-ascorbic acid, MTG, ITS, BMP4, VEGF, bFGF, SB 431542, SCF, TPO, FLT3, Sodium Pyruvate, β-Mercaptoethanol, NEAA, IL-7, IL-15, SB203580, SDF-1α, Dexamethasone, IL-21, and Anti-CD3 OKT3.
7. A culture medium for culturing pluripotent cells and differentiating them into T cells, said culture medium containing Rho activator I / II.
8. The culture medium according to claim 7, wherein the Rho activator I / II is selected from one or more activators of the group consisting of CN02, CN03 and CN04.
9. The culture medium according to any one of claims 7-8, wherein the concentration of the Rho activator I / II is 150-350 ng / mL.
10. The culture medium according to any one of claims 7-9, comprising one or more of the following factors: CHIR99021, Y-27632, GlutaMAX, L-ascorbic acid, MTG, ITS, BMP4, VEGF, bFGF, SB 431542, SCF, TPO, FLT3, Sodium Pyruvate, β-Mercaptoethanol, NEAA, IL-7, IL-15, SB203580, SDF-1α, Dexamethasone, IL-21, and Anti-CD3 OKT3.
